Drug Discovery Today: Disease Models This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Animal models for diabetes: genes, environment and health
Publication date: Summer 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 2 Author(s): Roger D. Cox (Source: Drug Discovery Today: Disease Models)
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

MicroRNA in rheumatoid arthritis: lessons from animal models of disease
Publication date: Autumn 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 3 Author(s): Clare Tange , Iain B. McInnes , Mariola Kurowska-Stolarska MicroRNAs (miRNAs) are a novel class of post-transcriptional regulators. In vitro studies suggest that a single miR can mediate profound effects on a variety of cellular activities ranging from cell cycle, motility and metabolism to effector function. This is facilitated by the capacity of miRNA to modulate several pathways by virtue of binding to multiple target mRNAs – which renders them attractive potential therapeutic targets. Several miRNAs are now...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

Micromanaging microRNAs: using murine models to study microRNAs in lung fibrosis
Publication date: Autumn 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 3 Author(s): Christian L. Lino Cardenas , Naftali Kaminski , Daniel J. Kass MicroRNAs are implicated in many biological and pathological processes and are emerging as key actors in lung health and disease. Specific patterns of dysregulated microRNAs have been found in idiopathic pulmonary fibrosis (IPF), an untreatable interstitial lung disease of unknown etiology. IPF is characterized by dramatic and extensive phenotypic changes in the lung that include alveolar cell hyperplasia, fibroblast proliferation and formation of myo...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

MicroRNAs and polycystic kidney disease
We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD. (Source: Drug Discovery Today: Disease Models)
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models
Publication date: Autumn 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 3 Author(s): Jeremy S. Duffield , Monica Grafals , Didier Portilla Chronic disease of the kidneys has reached epidemic proportions in industrialized nations. New therapies are urgently sought. Using a combination of animal models of kidney disease and human biopsy samples, a pattern of dysregulated microRNA expression has emerged which is common to chronic diseases. Several of these dysregulated microRNAs have recently been shown to have functional consequences for the disease process and therefore may be potential therapeuti...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

The role of miRNAs in animal models of liver fibrosis
Publication date: Autumn 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 3 Author(s): Christoph Roderburg , Tom Luedde Many chronic liver diseases are still not sufficiently treatable and often progress to liver cirrhosis representing a major global health burden. However, despite the enormous relevance of this disease, pharmacological strategies for prevention or treatment of hepatic fibrosis are still limited, underlining the need to establish a better understanding of the molecular mechanisms underlying the pathogenesis of hepatic cirrhosis. Since their discovery in 1993, miRNAs have emerged as ...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

MicroRNA and disease models: focus on cardiac fibrosis
Publication date: Autumn 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 3 Author(s): Jan Fiedler , Da-Hee Park , Thomas Thum A subset of regulatory non-coding RNAs, designated as microRNAs (miRNAs, miRs), emerged as strong post-transcriptional regulators. MiRNAs target (partially) complementary sequences of mRNAs thus repressing transcript expression and subsequently altering the cellular transcriptome. Cardiac diseases (e.g. development of fibrosis) are closely linked to deregulated gene expression and novel therapeutic interventions are needed to counteract disease progression. Interestingly, m...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

microRNAs in models of fibrosis
Publication date: Autumn 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 3 Author(s): Deidre A. MacKenna , B. Nelson Chau (Source: Drug Discovery Today: Disease Models)
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

Pluripotent stem cell-based models to investigate retinal pigmented epithelium function and disease
Publication date: Winter 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 4 Author(s): Duncan E. Crombie , Alice Pébay , Robyn H. Guymer , Kathryn C. Davidson Animal models do not always recapitulate or translate to human diseases. Pluripotent stem cells provide a self-renewing resource to generate mature cell types, including those of the retina. Furthermore, induced pluripotent stem cells derived from patients with genetic diseases can be differentiated into specialized cells to create in vitro disease models with precise pathogenic genotypes. Recent progress in deriving functional RPE cells fr...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

The chick as an animal model of eye disease
Publication date: Winter 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 4 Author(s): Paul M. Hocking , Jeremy A. Guggenheim A diverse range of chicken lines harbouring highly-penetrant, spontaneously-occurring mutations with an ocular phenotype have been identified over the past 40 years. These lines serve as models for human monogenic disorders including ocular albinism, retinal dystrophies such as Leber's congenital amaurosis, and coloboma, as well as the common complex traits glaucoma and myopia. Recent technical advances in gene targeting, mapping quantitative trait loci, and phenotypic charac...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

Drug and gene therapy of hereditary retinal disease in dog and cat models
Publication date: Winter 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 4 Author(s): Simon M. Petersen-Jones There are many different spontaneously occurring dog and cat retinal dystrophies that are the equivalent of human conditions such as Leber congenital amaurosis, retinitis pigmentosa and Best disease. These large animal species have eyes that are similar in size and dimensions and photoreceptor distribution to the human eyes. Some of these models have already proven valuable in preclinical proof-of-concept trials for gene and drug therapies. (Source: Drug Discovery Today: Disease Models)
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

Drug discovery in glaucoma and the role of animal models
Publication date: Winter 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 4 Author(s): Sara McNally , Colm J. O’Brien Glaucoma is a neurodegenerative disorder characterised by damage to inner layers of the retina and the optic nerve (ON). The slow degeneration of retinal ganglion cells (RGCs) and their axons results in a progressive loss of vision. To date, a wide variety of animal models have been used to study glaucoma disease mechanisms and these include monkey, dog, and rodent models. However, there remains no ideal model for studying glaucoma disease and this is largely due to its complexity....
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

Mouse models of diabetic retinopathy
Publication date: Winter 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 4 Author(s): D. Ramos , A. Carretero , M. Navarro , L. Mendes-Jorge , A. Rodriguez-Baeza , V. Nacher , J. Ruberte Despite many years of clinical and laboratory investigation, diabetic retinopathy remains the leading cause of vision impairment among working-aged people. Mouse models have been valuable tools in further understanding the pathophysiology of diabetic retinopathy and discovering and assessing new potential therapeutic agents. However, although numerous diabetic mouse models have been developed, none of these mo...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

Genetic models for cataracts
Publication date: Winter 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 4 Author(s): Jochen Graw Opacities of the eye lens (cataracts) are well known as congenital (and mainly hereditary) disorders and as age-related and rather complex diseases. For the hereditary, congenital forms, the mouse is actually the model of choice; however, for the rather age-related and complex forms of cataracts, the rat is also frequently used as model (particularly for diabetes- and UV-induced cataracts) (Source: Drug Discovery Today: Disease Models)
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research

Animal models of age-related macular degeneration
Publication date: Winter 2013 Source:Drug Discovery Today: Disease Models, Volume 10, Issue 4 Author(s): Srini Goverdhan , Heather Thomson , Andrew Lotery Animal models are crucial to study causative mechanisms and evaluate novel treatment strategies for blinding diseases like age-related macular degeneration (AMD). This brief review summarises commonly reported rodent and primate models of AMD. The different models require genetic/transgenic manipulation and differ in their ability to recapitulate human AMD features, with impact on costs and predictability for researchers. Laser-induced wet AMD models have cruciall...
Source: Drug Discovery Today: Disease Models - November 14, 2014 Category: Drugs & Pharmacology Source Type: research